NeoGenomics NEO Commercial insurance — NET REVENUE
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about NeoGenomics's commercial insurance — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NeoGenomics's commercial insurance — NET REVENUE?
- NeoGenomics (NEO) reported commercial insurance — NET REVENUE of $30.94M in Q1 2026.
- How has NeoGenomics's commercial insurance — NET REVENUE changed year-over-year?
- NeoGenomics's commercial insurance — NET REVENUE increased by 24.5% year-over-year, from $24.86M to $30.94M.
- What is the long-term trend for NeoGenomics's commercial insurance — NET REVENUE?
- Over 4 years (2021 to 2025), NeoGenomics's commercial insurance — NET REVENUE has grown at a 10.5% compound annual growth rate (CAGR), from $78.77M to $117.51M.
- What does commercial insurance — NET REVENUE mean?
- This metric represents the total revenue generated from genetic and molecular testing services reimbursed by private commercial insurance payers. It reflects the company's ability to secure favorable coverage policies and successfully navigate the billing and collection processes with non-governmental health plans. Growth in this segment indicates successful market penetration and effective management of the payer mix within the clinical diagnostics landscape.